We recently published 10 Big Names Bleed Double Digits. Organon & Co. (NYSE:OGN) is one of the worst-performing stocks on Tuesday.
Organon fell for a second day on Tuesday, shedding 13.13 percent to close at $8.4 apiece following a disappointing earnings performance in the second quarter of the year.
In its updated report, Organon & Co. (NYSE:OGN) said net income declined by 26 percent to $145 million from $195 million in the same period last year, while revenues dipped by 1 percent to $1.59 billion from $1.6 billion year-on-year.
“During the quarter, we paid down principal on our long-term debt and began implementing meaningful cost savings, which together set us on a path to achieve net leverage below 4.0x by the end of this year. We will aim to drive further improvement, with the goal of achieving net leverage of 3.5x or below by the end of 2026,” said Organon & Co. (NYSE:OGN) CEO Kevin Ali.
For full-year 2025, Organon & Co. (NYSE:OGN) has raised its revenue target to $6.275 billion to $6.375 billion, from the previous range of $6.125 billion to $6.325 billion.
Copyright: epstock / 123RF Stock Photo
It also declared a $0.02 cash dividend for each common share held as of August 15. The dividends are payable on September 11.
While we acknowledge the potential of OGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
